MX2019005397A - Proteinas de union a antigeno que antagonizan el receptor de leptina. - Google Patents
Proteinas de union a antigeno que antagonizan el receptor de leptina.Info
- Publication number
- MX2019005397A MX2019005397A MX2019005397A MX2019005397A MX2019005397A MX 2019005397 A MX2019005397 A MX 2019005397A MX 2019005397 A MX2019005397 A MX 2019005397A MX 2019005397 A MX2019005397 A MX 2019005397A MX 2019005397 A MX2019005397 A MX 2019005397A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- antigen
- lepr
- binding fragments
- bind
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención proporciona anticuerpos y fragmentos de unión a antígeno de anticuerpos que se unen al receptor de leptina (LEPR), y métodos para usarlos. De acuerdo con ciertas realizaciones, la invención incluye anticuerpos y fragmentos de unión a antígeno de anticuerpos que se unen a LEPR y antagonizan la señalización de LEPR. En ciertas realizaciones, la invención incluye anticuerpos y fragmentos de unión a antígeno de anticuerpos que se unen a LEPR en presencia o ausencia de leptina. En otras realizaciones, la invención incluye anticuerpos y fragmentos de unión a antígeno de anticuerpos que exhiben agonismo parcial de señalización LEPR. Los anticuerpos y fragmentos de unión a antígeno de la presente invención son útiles para el tratamiento de diversas afecciones, que incluyen, pero no se limitan a, caquexia por insuficiencia cardíaca congestiva, caquexia pulmonar y caquexia por cáncer, trastornos autoinmunes como enfermedad inflamatoria intestinal, lupus eritematoso, esclerosis múltiple, psoriasis, enfermedades cardiovasculares, presión arterial elevada, trastornos neurodegenerativos, depresión, cáncer como carcinoma hepatocelular, melanoma, cáncer de mama, y otras enfermedades y trastornos asociados con o causados por una elevada señalización de leptina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662419062P | 2016-11-08 | 2016-11-08 | |
| PCT/US2017/060690 WO2018089532A1 (en) | 2016-11-08 | 2017-11-08 | Antigen-binding proteins that antagonize leptin receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019005397A true MX2019005397A (es) | 2019-10-09 |
Family
ID=60409473
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019005397A MX2019005397A (es) | 2016-11-08 | 2017-11-08 | Proteinas de union a antigeno que antagonizan el receptor de leptina. |
| MX2023011233A MX2023011233A (es) | 2016-11-08 | 2019-05-08 | Proteinas de union a antigeno que antagonizan el receptor de leptina. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011233A MX2023011233A (es) | 2016-11-08 | 2019-05-08 | Proteinas de union a antigeno que antagonizan el receptor de leptina. |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10550192B2 (es) |
| EP (2) | EP3538554B1 (es) |
| JP (4) | JP7042816B2 (es) |
| KR (1) | KR102563568B1 (es) |
| CN (1) | CN110167965A (es) |
| AU (2) | AU2017359439B2 (es) |
| CA (1) | CA3043365A1 (es) |
| CL (3) | CL2019001263A1 (es) |
| CO (1) | CO2019004672A2 (es) |
| DK (1) | DK3538554T3 (es) |
| EA (1) | EA201991075A1 (es) |
| ES (1) | ES3040144T3 (es) |
| FI (1) | FI3538554T3 (es) |
| HR (1) | HRP20251165T1 (es) |
| IL (2) | IL266426B (es) |
| LT (1) | LT3538554T (es) |
| MA (1) | MA45801B1 (es) |
| MX (2) | MX2019005397A (es) |
| MY (2) | MY191256A (es) |
| PH (1) | PH12019500988A1 (es) |
| PL (1) | PL3538554T3 (es) |
| PT (1) | PT3538554T (es) |
| RS (1) | RS67214B1 (es) |
| SG (1) | SG10201913470SA (es) |
| SI (1) | SI3538554T1 (es) |
| SM (1) | SMT202500327T1 (es) |
| UA (1) | UA127678C2 (es) |
| WO (1) | WO2018089532A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI824372B (zh) | 2015-10-12 | 2023-12-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| FI3538554T3 (fi) | 2016-11-08 | 2025-09-24 | Regeneron Pharma | Antigeeniä sitovia proteiineja, jotka antagonisoivat leptiinireseptoria |
| BR112020012011A2 (pt) | 2017-12-18 | 2020-11-24 | Regeneron Pharmaceuticals, Inc. | moléculas de ligação a antígeno biespecífica isolada e de ligação a antígeno biespecífica ou cadeia de imunoglobulina, composição farmacêutica, recipiente ou dispositivo de injeção, ácido nucleico isolado, vetor isolado, célula hospedeira isolada, métodos para tratar uma doença ou condição, para tratar uma condição de lipodistrofia em um sujeito, para produzir uma molécula de ligação a antígeno biespecífica, e, para administrar uma molécula de ligação a antígeno biespecífica isolada ou composição farmacêutica. |
| US11608381B2 (en) | 2018-04-06 | 2023-03-21 | Regeneron Pharmaceuticals, Inc. | Methods of treatment using a leptin receptor agonist antibody |
| WO2020016160A1 (en) * | 2018-07-16 | 2020-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat neurological diseases |
| WO2020131910A1 (en) | 2018-12-18 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, gdf8 and activin a |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| US20230263673A1 (en) * | 2020-07-17 | 2023-08-24 | Sumitomo Seika Chemicals Co., Ltd. | Absorber |
| JP2023543409A (ja) * | 2020-09-15 | 2023-10-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 疼痛に対するｌｅｐｒアゴニストの使用 |
| CN118436632B (zh) * | 2024-07-05 | 2024-08-30 | 四川大学华西第二医院 | Teriflunomide在制备预防和/或治疗原发性纤毛不动综合征的药物中的用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643748A (en) | 1994-09-14 | 1997-07-01 | Progenitor, Inc. | HU-B1.219, a novel human hematopoietin receptor |
| US6451523B1 (en) | 1994-09-14 | 2002-09-17 | Interneuron Pharmaceuticals, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
| US5912123A (en) | 1994-09-14 | 1999-06-15 | Progenitor, Inc. | Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology |
| US5856098A (en) | 1994-09-14 | 1999-01-05 | Progenitor, Inc. | Detection of a leptin receptor variant |
| US6482927B1 (en) | 1995-11-27 | 2002-11-19 | Millennium Pharmaceuticals, Inc. | Chimeric proteins comprising the extracellular domain of murine Ob receptor |
| US6977240B1 (en) | 1995-11-27 | 2005-12-20 | Millenium Pharmaceuticals, Inc. | Methods of using the OB receptor antibodies to treat bodyweight disorders |
| US20050019325A1 (en) * | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
| DE69739677D1 (de) | 1996-01-08 | 2010-01-07 | Genentech Inc | OB Rezeptor-Variante und Liganden |
| US7063958B1 (en) * | 1996-01-16 | 2006-06-20 | The Rockefeller University | Nucleic acids db, the receptor for leptin |
| AU2476301A (en) | 1996-01-16 | 2001-05-24 | Rockefeller University, The | DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof |
| AU1833197A (en) | 1996-01-18 | 1997-08-11 | Progenitor, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
| DE69735477T2 (de) | 1996-01-23 | 2006-11-30 | Indevus Pharmaceuticals, Inc., Lexington | Process zur verwendung des obese-gens und seines genprodukts zur stimulierung der entwicklung von haemotopoietischen zellen |
| US7067472B1 (en) | 1996-06-04 | 2006-06-27 | The Scripps Research Institute | Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies |
| US5965521A (en) | 1997-02-25 | 1999-10-12 | Eli Lilly Company | Pulsatile delivery of leptin receptor ligands |
| IL120733A0 (en) | 1997-04-29 | 1997-08-14 | Yeda Res & Dev | Leptin as an inhibitor of cell proliferation |
| US6696411B1 (en) | 1998-04-22 | 2004-02-24 | Cornell Research Foundation, Inc. | Canine erythropoietin gene and recombinant protein |
| AU767068B2 (en) | 1999-06-11 | 2003-10-30 | Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of leptin activity |
| US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
| FR2852397B1 (fr) | 2003-03-10 | 2005-04-29 | Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal. | |
| ATE364630T1 (de) * | 2003-08-21 | 2007-07-15 | Vlaams Interuniv Inst Biotech | Neuer leptin-antagonist |
| DE10353593A1 (de) * | 2003-11-17 | 2005-06-23 | Klinikum der Universität München Großhadern-Innenstadt | Leptinantagonist und Verfahren zur quantitativen Messung von Leptin |
| US8969291B2 (en) | 2004-10-08 | 2015-03-03 | Enzo Therapeutics, Inc. | Methods for decreasing leptin levels or activity for treating inflammation |
| US7863240B2 (en) | 2004-10-08 | 2011-01-04 | Enzo Therapeutics, Inc. | Methods and uses of leptin in hepatocellular carcinoma |
| WO2006053883A1 (en) | 2004-11-18 | 2006-05-26 | Vib Vzw | Fibronectin iii domain as leptin receptor antagonists |
| US7307142B2 (en) * | 2004-11-26 | 2007-12-11 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | Leptin antagonists |
| JP5255435B2 (ja) | 2005-04-26 | 2013-08-07 | メディミューン，エルエルシー | ヒンジドメイン操作による抗体エフェクター機能の調節 |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| GB0715216D0 (en) | 2007-08-03 | 2007-09-12 | Asterion Ltd | Leptin |
| EP2356270B1 (en) | 2008-11-07 | 2016-08-24 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| KR101962483B1 (ko) | 2010-11-17 | 2019-03-29 | 추가이 세이야쿠 가부시키가이샤 | 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자 |
| MX2013009151A (es) | 2011-02-10 | 2013-08-29 | Roche Glycart Ag | Inmunoterapia mejorada. |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| MY170126A (en) | 2012-09-12 | 2019-07-05 | Genzyme Corp | Fc containing polypeptides with altered glycosylation and reduced effector function |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| KR101764800B1 (ko) * | 2013-02-20 | 2017-08-04 | 리제너론 파마슈티칼스 인코포레이티드 | 변형된 면역글로불린 중쇄 서열을 갖는 비인간 동물 |
| EP3108255B1 (en) | 2014-02-18 | 2020-08-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway |
| TWI824372B (zh) | 2015-10-12 | 2023-12-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| FI3538554T3 (fi) | 2016-11-08 | 2025-09-24 | Regeneron Pharma | Antigeeniä sitovia proteiineja, jotka antagonisoivat leptiinireseptoria |
-
2017
- 2017-11-08 FI FIEP17801273.8T patent/FI3538554T3/fi active
- 2017-11-08 SI SI201731619T patent/SI3538554T1/sl unknown
- 2017-11-08 CN CN201780082335.4A patent/CN110167965A/zh active Pending
- 2017-11-08 LT LTEPPCT/US2017/060690T patent/LT3538554T/lt unknown
- 2017-11-08 DK DK17801273.8T patent/DK3538554T3/da active
- 2017-11-08 PL PL17801273.8T patent/PL3538554T3/pl unknown
- 2017-11-08 SM SM20250327T patent/SMT202500327T1/it unknown
- 2017-11-08 MX MX2019005397A patent/MX2019005397A/es unknown
- 2017-11-08 WO PCT/US2017/060690 patent/WO2018089532A1/en not_active Ceased
- 2017-11-08 MA MA45801A patent/MA45801B1/fr unknown
- 2017-11-08 KR KR1020197016377A patent/KR102563568B1/ko active Active
- 2017-11-08 MY MYPI2019002549A patent/MY191256A/en unknown
- 2017-11-08 HR HRP20251165TT patent/HRP20251165T1/hr unknown
- 2017-11-08 SG SG10201913470SA patent/SG10201913470SA/en unknown
- 2017-11-08 AU AU2017359439A patent/AU2017359439B2/en active Active
- 2017-11-08 EP EP17801273.8A patent/EP3538554B1/en active Active
- 2017-11-08 RS RS20250925A patent/RS67214B1/sr unknown
- 2017-11-08 EP EP25187542.3A patent/EP4613772A3/en active Pending
- 2017-11-08 CA CA3043365A patent/CA3043365A1/en active Pending
- 2017-11-08 JP JP2019523865A patent/JP7042816B2/ja active Active
- 2017-11-08 US US15/807,426 patent/US10550192B2/en active Active
- 2017-11-08 EA EA201991075A patent/EA201991075A1/ru unknown
- 2017-11-08 MY MYPI2022002957A patent/MY203682A/en unknown
- 2017-11-08 UA UAA201906354A patent/UA127678C2/uk unknown
- 2017-11-08 ES ES17801273T patent/ES3040144T3/es active Active
- 2017-11-08 PT PT178012738T patent/PT3538554T/pt unknown
-
2019
- 2019-05-02 IL IL266426A patent/IL266426B/en active IP Right Grant
- 2019-05-03 PH PH12019500988A patent/PH12019500988A1/en unknown
- 2019-05-07 CO CONC2019/0004672A patent/CO2019004672A2/es unknown
- 2019-05-08 CL CL2019001263A patent/CL2019001263A1/es unknown
- 2019-05-08 MX MX2023011233A patent/MX2023011233A/es unknown
-
2020
- 2020-01-07 US US16/736,760 patent/US11535675B2/en active Active
- 2020-01-30 IL IL272358A patent/IL272358B/en unknown
- 2020-03-05 CL CL2020000549A patent/CL2020000549A1/es unknown
- 2020-04-16 CL CL2020001023A patent/CL2020001023A1/es unknown
-
2021
- 2021-12-21 JP JP2021206917A patent/JP2022031969A/ja active Pending
-
2022
- 2022-11-17 US US18/056,411 patent/US20230235068A1/en active Pending
-
2023
- 2023-05-02 JP JP2023076083A patent/JP7611292B2/ja active Active
-
2024
- 2024-05-31 JP JP2024088870A patent/JP2024109952A/ja active Pending
-
2025
- 2025-02-28 AU AU2025201454A patent/AU2025201454A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019004672A2 (es) | Proteínas de unión a antígeno que antagonizan el receptor de leptina | |
| CY1125260T1 (el) | Παραγοντες δεσμευσης tigit και χρησεις τους | |
| CO2020009091A2 (es) | Exosomas para inmunooncología y terapia antiinflamatoria | |
| PH12020552178A1 (en) | Anti-il36r antibodies | |
| EA201890131A1 (ru) | Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38 | |
| EA201791050A1 (ru) | Конъюгаты антител и лекарственных средств | |
| PH12020551443A1 (en) | Use of anti-il-36r antibodies for treatment of inflammatory bowel disease | |
| EA201890572A1 (ru) | Биофармацевтические композиции | |
| JO3537B1 (ar) | أجسام مضادة لييفية أولية لاميلويد بيتا الببتيد ab المحسنة | |
| EA202090401A1 (ru) | Анти-tim-3 антитела и их применение | |
| MX2023012740A (es) | Anticuerpos antifactor de la coagulacion xi. | |
| EA201890442A1 (ru) | Получение фоторецепторов для лечения заболеваний сетчатки | |
| MX2021007119A (es) | Metodos para producir anticuerpos heterodimericos. | |
| MX2017008096A (es) | Pestivirus. | |
| MX2024012972A (es) | Vedolizumab para el tratamiento de pacientes pediatricos | |
| EA201692395A1 (ru) | Новые соединения | |
| IN2015CH01182A (es) | ||
| CO2019002550A2 (es) | Anticuerpos anti-gm-csf y usos de los mismos | |
| EA202090670A1 (ru) | Способ получения тубулизинов и их промежуточных соединений | |
| EA201990493A1 (ru) | Антитела к гм-ксф и их применения | |
| IL268274A (en) | Methods for diagnosing malignant diseases | |
| BR112017006177A2 (pt) | compostos imunoestimuladores | |
| EA202092133A1 (ru) | Применение антител против il-36r для лечения воспалительного заболевания кишечника | |
| IN2013MU01918A (es) | ||
| EA202092743A1 (ru) | Антитела к il36r |